

- 1/29 -




Figure 1

- 2/29 -





Figure 2

SUBSTITUTE SHEET (RULE 26) RO/AU




	Benign	PIN	Establishment Cancer	Advanced Cancer
Intensity ≥ 2	95	58	74	74
Intensity ≤ 1		28	1	1
No staining	0	0	0	0
Total *	95	86	75	75
Sensitivity (%)	100	100	100	100
Specificity (%)	100	67.44	98.67	98.67

- Data set from test cohort of 116 patients with five tissue microarray biopsycorresper patient.

Figure 3

- 4/29 -




	Benign	PIN	Establishment Cancer	Advanced Cancer
Intensity ≥ 2	19	80	86	55
Intensity ≤ 1	55	7	1	3
No staining	0	0	0	0
Total *	74	87	87	58
Sensitivity (%)	100	100	100	100
Specificity (%)	25.67	91.95	98.85	94.82

- Data set from test cohort of 116 patients with five tissue microarray biopsycorresper patient.

Figure 4

- 5/29 -



- Data set from test cohort of 116 patients with five tissue microarray biopsycorresper patient.

Figure 5

- 6/29 -




Figure 6

- 7/29 -




Figure 7


SUBSTITUTE SHEET (RULE 26) RO/AU

- 8/29 -


PIN
(Prostatic Intraepithelial Neoplasia)



Advanced Cancer



Benign
(Basal cell staining)



Establishment Cancer




Figure 8


SUBSTITUTE SHEET (RULE 26) RO/AU

- 9/29 -

BCH/PIN
(Prostatic Intraepithelial Neoplasia)



Advanced Cancer



Benign
(Basal cell staining)



Establishment Cancer





Figure 9

SUBSTITUTE SHEET (RULE 26) RO/AU

- 10/29 -

**Figure 10**




Figure 11

- 12/29 -




Figure 12

- 13/29 -

Prostate Cancer Case Study - ISUP Group 2 (3+4)




Figure 13

SUBSTITUTE SHEET (RULE 26) RO/AU

- 14/29 -

Prostate Cancer Case Study - ISUP Group 3 (4+3)




Figure 14

- 15/29 -




Figure 15

- 16/29 -




Figure 16

- 17/29 -




Figure 17

SUBSTITUTE SHEET (RULE 26) RO/AU

- 18/29 -

**Appl-1, Sortilin-1 & Syndecan-1 Biomarker Utility for Prostate Cancer
Pathology Assessment**

Market Indication	Biomarker	Clinical Utility
Cancer Detection	Appl-1	• Defines the extent of cancer with $\geq$ with 95% sensitivity and specificity • Confirms prostate cancer diagnosis • Identifies areas of concern, to guide the pathologist in Gleason Grading with Sortilin-1 establishment and Syndecan-1 advanced prostate cancer biomarkers
Prediction of Clinical Outcome	Sortilin-1 Syndecan-1	• Improve the reliability of Gleason Grading/ISUP grade grouping • Clearly identify patients with ISUP grade group 1 (establishment cancer) that are suitable for active surveillance • Identify patients at diagnosis who are at risk of biochemical recurrence and clinical recurrence • Determine which patients will have a poor outcome and need immediate radical intervention (e.g. prostatectomy, radiation therapy)

Figure 18

SUBSTITUTE SHEET (RULE 26) RO/AU

- 19/29 -

H&E

	Intraclass Correlation ^b	95% Confidence Interval		F Test with True Value 0			
		Lower Bound	Upper Bound	Value	df1	df2	Sig
Single Measures	 .728 ^a	.687	.767	11.741	301	903	.000
Average Measures	.915 ^c	.898	.929	11.741	301	903	.000

IHC

	Intraclass Correlation ^b	95% Confidence Interval		F Test with True Value 0			
		Lower Bound	Upper Bound	Value	df1	df2	Sig
Single Measures	 .814 ^a	.783	.842	18.788	301	903	.000
Average Measures	.946 ^c	.935	.955	18.788	301	903	.000

Two-way mixed effects model where people effects are random and measures effects are fixed.

- The estimator is the same, whether the interaction effect is present or not.
- Type A intraclass correlation coefficients using an absolute agreement definition.
- This estimate is computed assuming the interaction effect is absent, because it is not estimable otherwise.

Figure 19






Figure 20

- 21/29 -

**Figure 21**

SUBSTITUTE SHEET (RULE 26) RO/AU



	ISUP 1	ISUP 2	ISUP 3	ISUP 4	ISUP 5	TOTAL
EV1+ /EV3 +				2	4	6
EV1+ /EV2+ /EV3+		8	1	1	2	12




Figure 22

Consensus Cross-Tabulation Data for ISUP groupings by H&E vs IHC

H&E ISUP Grade Grouping									
	0	1	2	3	4	5	Total		
0	39	10	0	0	0	0	49		
1	12	18	9	1	0	0	40		
2	1	14	49	13	2	0	79		
3	1	2	14	23	11	1	52		
4	0	0	4	5	18	7	34		
5	0	0	0	2	15	11	28		
Total	53	44	76	44	46	19	302		


- * APCB cohort data
- * Up to 8-10 year longitudinal patient history
- * All patients re-graded for ISUP grouping
- * n = 302 samples
- * n = 4 operators

0543

"Improved cancer detection by IHC results in significant shifts in RARP patient groupings for prostate cancer patients"

Figure 23

- 24/29 -




Pearson $\chi^2 = 57.7158$; $P < 0.0001$ ($n = 100$ Control and $n = 96$ Pca human plasmas)

Limitations: Controls could contain cancer patients (randomly selected re: 18/100 in healthy)

Cancer patients not confirmed by immune histology (re: 5/96 as "0" in Pca)

Appl-1 Prostate Cancer Plasma Assay ROC Analysis




"Significant capacity to detect prostate cancer using human plasma samples"

Figure 24

SUBSTITUTE SHEET (RULE 26) RO/AU

- 25/29 -

**Figure 25**




Figure 26





Figure 27

- 28/29 -

**Figure 28**

SUBSTITUTE SHEET (RULE 26) RO/AU




Figure 29